1. Home
  2. VGZ vs FHTX Comparison

VGZ vs FHTX Comparison

Compare VGZ & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vista Gold Corp

VGZ

Vista Gold Corp

HOLD

Current Price

$2.03

Market Cap

295.7M

Sector

N/A

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$4.79

Market Cap

323.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGZ
FHTX
Founded
1983
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
295.7M
323.4M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
VGZ
FHTX
Price
$2.03
$4.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$3.75
$11.50
AVG Volume (30 Days)
1.2M
109.1K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.32
EPS
N/A
N/A
Revenue
N/A
$30,909,000.00
Revenue This Year
N/A
$8.89
Revenue Next Year
N/A
$20.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
36.75
52 Week Low
$0.88
$3.27
52 Week High
$3.13
$6.95

Technical Indicators

Market Signals
Indicator
VGZ
FHTX
Relative Strength Index (RSI) 44.63 43.68
Support Level $1.75 $4.44
Resistance Level $2.46 $5.82
Average True Range (ATR) 0.10 0.28
MACD 0.01 0.01
Stochastic Oscillator 19.44 27.70

Price Performance

Historical Comparison
VGZ
FHTX

About VGZ Vista Gold Corp

Vista Gold Corp operates as a development-stage company in the gold mining industry. Its flagship asset is the Mt Todd Gold Project, a development-stage gold deposit located in the Tier-1 jurisdiction of Northern Territory, Australia. Mt Todd offers a large gold mineral reserve, development optionality, expansion opportunities, exploration upside, local infrastructure, community support, and demonstrated economic feasibility. It operates in one reportable segment, consisting of acquisition, exploration and evaluation activities which are focused on Australia.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Share on Social Networks: